Vandetanib (BioDeep_00000388963)
代谢物信息卡片
Vandetanib(ZD6474)
化学式: C22H24BrFN4O2 (474.10665559999995)
中文名称: 凡德他尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC
InChI: InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:49960
- KEGGdrug: D06407
- PubChem: 3081361
- Metlin: METLIN85197
- DrugBank: DB05294
- ChEMBL: CHEMBL24828
- CAS: 338992-00-0
- CAS: 443913-73-3
- PMhub: MS000238996
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Weina Ma, Man Zhu, Bo Wang, Zhengyan Gong, Xia Du, Tianfeng Yang, Xianpeng Shi, Bingling Dai, Yingzhuan Zhan, Dongdong Zhang, Yanhong Ji, Yang Wang, Song Li, Yanmin Zhang. Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4.
Molecular oncology.
2022 07; 16(14):2747-2765. doi:
10.1002/1878-0261.13270. [PMID: 35689424] - Ali S Abdelhameed, Mohamed W Attwa, Mohamed I Attia, Amer M Alanazi, Obaid S Alruqi, Haitham AlRabiah. Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2022 Jan; 264(?):120336. doi:
10.1016/j.saa.2021.120336. [PMID: 34481256] - Livio Racané, Maja Cindrić, Ivo Zlatar, Tatjana Kezele, Astrid Milić, Karmen Brajša, Marijana Hranjec. Preclinical in vitro screening of newly synthesised amidino substituted benzimidazoles and benzothiazoles.
Journal of enzyme inhibition and medicinal chemistry.
2021 Dec; 36(1):163-174. doi:
10.1080/14756366.2020.1850711. [PMID: 33404264] - Ali S Abdelhameed, Eman S Hassan, Mohamed W Attwa, Nasser S Al-Shakliah, Amer M Alanazi, Haitham AlRabiah. Simple and efficient spectroscopic-based univariate sequential methods for simultaneous quantitative analysis of vandetanib, dasatinib, and sorafenib in pharmaceutical preparations and biological fluids.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2021 Nov; 260(?):119987. doi:
10.1016/j.saa.2021.119987. [PMID: 34082354] - Yuko Tanihara, Satohiro Masuda, Ken-Ichi Inui. Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2021 Mar; 158(?):105666. doi:
10.1016/j.ejps.2020.105666. [PMID: 33296710] - Laura Valerio, Valeria Bottici, Antonio Matrone, Paolo Piaggi, David Viola, Virginia Cappagli, Laura Agate, Eleonora Molinaro, Raffaele Ciampi, Alessia Tacito, Teresa Ramone, Cristina Romei, Rossella Elisei. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Endocrine-related cancer.
2020 01; 27(2):97-110. doi:
NULL. [PMID: 31804969] - Rafael Duran, Julien Namur, Florentina Pascale, Peter Czuczman, Zainab Bascal, Hugh Kilpatrick, Rhys Whomsley, Samantha Ryan, Andrew L Lewis, Alban Denys. Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer.
Radiology.
2019 12; 293(3):695-703. doi:
10.1148/radiol.2019190305. [PMID: 31617791] - Huiqiang Wei, Yuqing Duan, Wenfeng Gou, Jie Cui, Hongxin Ning, Deguan Li, Yong Qin, Qiang Liu, Yiliang Li. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
European journal of medicinal chemistry.
2019 Nov; 181(?):111552. doi:
10.1016/j.ejmech.2019.07.055. [PMID: 31387063] - Alice Hagan, Marcus Caine, Cara Press, Wendy M Macfarlane, Gary Phillips, Andrew W Lloyd, Peter Czuczman, Hugh Kilpatrick, Zainab Bascal, Yiqing Tang, Pedro Garcia, Andrew L Lewis. Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2019 Aug; 136(?):104943. doi:
10.1016/j.ejps.2019.05.021. [PMID: 31152772] - Hany W Darwish, Ahmed H Bakheit, Nasser S Al-Shakliah, Ibrahim A Darwish. Development of novel response surface methodology-assisted micellar enhanced synchronous spectrofluorimetric method for determination of vandetanib in tablets, human plasma and urine.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2019 Apr; 213(?):272-280. doi:
10.1016/j.saa.2019.01.056. [PMID: 30703710] - Pedro Arriola-Villalobos, Blanca Benito-Pascual, David Díaz-Valle, José M Benítez-Del-Castillo. Confocal Microscopy Observation of Cornea Verticillata After Vandetanib Therapy for Medullary Thyroid Carcinoma.
Cornea.
2018 Jun; 37(6):789-792. doi:
10.1097/ico.0000000000001560. [PMID: 29521690] - Paola Romeo, Carla Colombo, Roberta Granata, Giuseppina Calareso, Ambra Vittoria Gualeni, Matteo Dugo, Loris De Cecco, Maria Grazia Rizzetti, Angela Zanframundo, Antonella Aiello, Maria Luisa Carcangiu, Annunziata Gloghini, Stefano Ferrero, Lisa Licitra, Angela Greco, Laura Fugazzola, Laura Deborah Locati, Maria Grazia Borrello. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
Endocrine-related cancer.
2018 03; 25(3):217-231. doi:
10.1530/erc-17-0389. [PMID: 29298817] - Julien Hadoux, Martin Schlumberger. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Best practice & research. Clinical endocrinology & metabolism.
2017 06; 31(3):335-347. doi:
10.1016/j.beem.2017.04.009. [PMID: 28911729] - Valérie Cochin, Marine Gross-Goupil, Alain Ravaud, Yann Godbert, Sylvestre Le Moulec. [Cabozantinib: Mechanism of action, efficacy and indications].
Bulletin du cancer.
2017 May; 104(5):393-401. doi:
10.1016/j.bulcan.2017.03.013. [PMID: 28477875] - Anne-Cécile Paepegaey, Béatrix Cochand-Priollet, Estelle Louiset, Pierre-Olivier Sarfati, Marco Alifano, Nelly Burnichon, Marie Bienvenu-Perrard, Najiba Lahlou, Léopoldine Bricaire, Lionel Groussin. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
Thyroid : official journal of the American Thyroid Association.
2017 04; 27(4):587-590. doi:
10.1089/thy.2016.0334. [PMID: 28068878] - Keita Uchino, Masato Komoda, Junichi Tomomatsu, Takahiro Okamoto, Kiyomi Horiuchi, Akihito Tsuji, Yasuhiro Ito, Takuya Todo, Ki Rito, Shunji Takahashi. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
2017 Feb; 23(2):149-156. doi:
10.4158/ep161259.or. [PMID: 27819766] - Alban Denys, Peter Czuczman, David Grey, Zainab Bascal, Rhys Whomsley, Hugh Kilpatrick, Andrew L Lewis. Vandetanib-eluting Radiopaque Beads: In vivo Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization.
Theranostics.
2017; 7(8):2164-2176. doi:
10.7150/thno.19652. [PMID: 28740542] - Anne R Tinning, Boye L Jensen, Iben Johnsen, Daian Chen, Thomas M Coffman, Kirsten Madsen. Vascular endothelial growth factor signaling is necessary for expansion of medullary microvessels during postnatal kidney development.
American journal of physiology. Renal physiology.
2016 09; 311(3):F586-99. doi:
10.1152/ajprenal.00221.2016. [PMID: 27413199] - Md Zahirul Kabir, Shevin R Feroz, Abdul Kadir Mukarram, Zazali Alias, Saharuddin B Mohamad, Saad Tayyab. Interaction of a tyrosine kinase inhibitor, vandetanib with human serum albumin as studied by fluorescence quenching and molecular docking.
Journal of biomolecular structure & dynamics.
2016 Aug; 34(8):1693-704. doi:
10.1080/07391102.2015.1089187. [PMID: 26331959] - Marie Bretagne, Pascaline Boudou-Rouquette, Olivier Huillard, Audrey Thomas-Schoemann, Anne Chahwakilian, Galdric Orvoen, Jennifer Arrondeau, Camille Tlemsani, Anatole Cessot, Laure Cabanes, Benoit Blanchet, Romain Coriat, Jérôme Alexandre, François Goldwasser. [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Bulletin du cancer.
2016 Mar; 103(3):259-72. doi:
10.1016/j.bulcan.2015.10.020. [PMID: 26832420] - Fan-Wei Peng, Ji Xuan, Ting-Ting Wu, Jia-Yu Xue, Zi-Wei Ren, Da-Ke Liu, Xiu-Qi Wang, Xin-Hang Chen, Jia-Wei Zhang, Yun-Gen Xu, Lei Shi. Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC.
European journal of medicinal chemistry.
2016 Feb; 109(?):1-12. doi:
10.1016/j.ejmech.2015.12.033. [PMID: 26741358] - Fan-Wei Peng, Ting-Ting Wu, Zi-Wei Ren, Jia-Yu Xue, Lei Shi. Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.
Bioorganic & medicinal chemistry letters.
2015 Nov; 25(22):5137-41. doi:
10.1016/j.bmcl.2015.10.006. [PMID: 26475519] - R A Werner, J S Schmid, D O Muegge, K Lückerath, T Higuchi, H Hänscheid, I Grelle, C Reiners, K Herrmann, A K Buck, C Lapa. Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
Medicine.
2015 Nov; 94(45):e2016. doi:
10.1097/md.0000000000002016. [PMID: 26559299] - Michael C Kreissl, M Fassnacht, S P Mueller. Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects.
Nuklearmedizin. Nuclear medicine.
2015; 54(3):88-93. doi:
10.1055/s-0037-1616607. [PMID: 26105716] - Carole Sourbier, Christopher J Ricketts, Shingo Matsumoto, Daniel R Crooks, Pei-Jyun Liao, Philip Z Mannes, Youfeng Yang, Ming-Hui Wei, Gaurav Srivastava, Sanchari Ghosh, Viola Chen, Cathy D Vocke, Maria Merino, Ramaprasad Srinivasan, Murali C Krishna, James B Mitchell, Ann Marie Pendergast, Tracey A Rouault, Len Neckers, W Marston Linehan. Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.
Cancer cell.
2014 Dec; 26(6):840-850. doi:
10.1016/j.ccell.2014.10.005. [PMID: 25490448] - William G Kaelin. DisABLing kidney cancers caused by fumarate hydratase mutations.
Cancer cell.
2014 Dec; 26(6):779-780. doi:
10.1016/j.ccell.2014.11.022. [PMID: 25490441] - Susanne Johansson, Jessica Read, Stuart Oliver, Mark Steinberg, Yan Li, Eleanor Lisbon, David Mathews, Philip T Leese, Paul Martin. Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Clinical pharmacokinetics.
2014 Sep; 53(9):837-47. doi:
10.1007/s40262-014-0161-2. [PMID: 25117183] - A A Nella, M B Lodish, E Fox, F M Balis, M M Quezado, P O Whitcomb, J Derdak, E Kebebew, B C Widemann, C A Stratakis. Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.
The Journal of clinical endocrinology and metabolism.
2014 Sep; 99(9):3055-9. doi:
10.1210/jc.2013-4340. [PMID: 24617713] - Arun A Azad, Emma K Beardsley, Sebastian J Hotte, Susan L Ellard, Lawrence Klotz, Joseph Chin, Christian Kollmannsberger, Som D Mukherjee, Kim N Chi. A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
Investigational new drugs.
2014 Aug; 32(4):746-52. doi:
10.1007/s10637-014-0091-8. [PMID: 24671507] - Alessia Salvador, Daniela Vedaldi, Paola Brun, Stefano Dall'Acqua. Vandetanib-induced phototoxicity in human keratinocytes NCTC-2544.
Toxicology in vitro : an international journal published in association with BIBRA.
2014 Aug; 28(5):803-11. doi:
10.1016/j.tiv.2014.03.007. [PMID: 24681205] - Mark J Clemons, Brandy Cochrane, Gregory R Pond, Nadia Califaretti, Stephen K L Chia, Rebecca Alexandra Dent, Xinni Song, Andre Robidoux, Sameer Parpia, David Warr, Daniel Rayson, Kathleen I Pritchard, Mark N Levine. Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
Breast cancer research and treatment.
2014 Jul; 146(1):153-62. doi:
10.1007/s10549-014-3015-6. [PMID: 24924416] - Robert L Coleman, James Moon, Anil K Sood, Wei Hu, James E Delmore, Albert J Bonebrake, Garnet L Anderson, Setsuko K Chambers, Maurie Markman. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
European journal of cancer (Oxford, England : 1990).
2014 Jun; 50(9):1638-48. doi:
10.1016/j.ejca.2014.03.005. [PMID: 24709487] - Hongjun Lin, Dandan Cui, Zhixing Cao, Qian Bu, Youzhi Xu, Yinglan Zhao. Validation of a high-performance liquid chromatographic ultraviolet detection method for the quantification of vandetanib in rat plasma and its application to pharmacokinetic studies.
Journal of cancer research and therapeutics.
2014 Jan; 10(1):84-8. doi:
10.4103/0973-1482.131393. [PMID: 24762492] - Hong Shen, Zheng Yang, Weiping Zhao, Yueping Zhang, A David Rodrigues. Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance.
Drug metabolism and disposition: the biological fate of chemicals.
2013 Dec; 41(12):2095-103. doi:
10.1124/dmd.113.053215. [PMID: 24026623] - Elizabeth Fox, Brigitte C Widemann, Meredith K Chuk, Leigh Marcus, Alberta Aikin, Patricia O Whitcomb, Maria J Merino, Maya Lodish, Eva Dombi, Seth M Steinberg, Samuel A Wells, Frank M Balis. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013 Aug; 19(15):4239-48. doi:
10.1158/1078-0432.ccr-13-0071. [PMID: 23766359] - Alberto Broniscer, Sharyn D Baker, Cynthia Wetmore, Atmaram S Pai Panandiker, Jie Huang, Andrew M Davidoff, Arzu Onar-Thomas, John C Panetta, Thomas K Chin, Thomas E Merchant, Justin N Baker, Sue C Kaste, Amar Gajjar, Clinton F Stewart. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013 Jun; 19(11):3050-8. doi:
10.1158/1078-0432.ccr-13-0306. [PMID: 23536435] - Marie-Hélène Massicotte, Isabelle Borget, Sophie Broutin, Vickie E Baracos, Sophie Leboulleux, Eric Baudin, Angelo Paci, Alain Deroussent, Martin Schlumberger, Sami Antoun. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.
The Journal of clinical endocrinology and metabolism.
2013 Jun; 98(6):2401-8. doi:
10.1210/jc.2013-1115. [PMID: 23543666] - Irina Andriamanana, Ines Gana, Bénédicte Duretz, Anne Hulin. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2013 May; 926(?):83-91. doi:
10.1016/j.jchromb.2013.01.037. [PMID: 23562906] - Anne S Tsao, Suyu Liu, J Jack Lee, Christine M Alden, George R Blumenschein, Roy Herbst, Suzanne E Davis, Edward Kim, Scott Lippman, John Heymach, Hai Tran, XiMing Tang, Ignacio Wistuba, Waun Ki Hong. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2013 May; 8(5):658-61. doi:
10.1097/jto.0b013e31828d08ae. [PMID: 23584298] - C Monneret. [Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].
Annales pharmaceutiques francaises.
2013 Mar; 71(2):95-103. doi:
10.1016/j.pharma.2013.01.004. [PMID: 23537410] - Andrew Advani, Kim A Connelly, Suzanne L Advani, Kerri Thai, Yuan Zhang, Darren J Kelly, Richard E Gilbert. Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes.
BioMed research international.
2013; 2013(?):201475. doi:
10.1155/2013/201475. [PMID: 24063000] - Shanthi Sivendran, Ziyue Liu, Louis J Portas, Menggang Yu, Noah Hahn, Guru Sonpavde, William K Oh, Matthew D Galsky. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
Cancer treatment reviews.
2012 Nov; 38(7):919-25. doi:
10.1016/j.ctrv.2012.05.001. [PMID: 22651902] - Mukul Minocha, Varun Khurana, Bin Qin, Dhananjay Pal, Ashim K Mitra. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
International journal of pharmaceutics.
2012 Oct; 436(1-2):127-34. doi:
10.1016/j.ijpharm.2012.05.038. [PMID: 22688250] - Mukul Minocha, Varun Khurana, Bin Qin, Dhananjay Pal, Ashim K Mitra. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
International journal of pharmaceutics.
2012 Sep; 434(1-2):306-14. doi:
10.1016/j.ijpharm.2012.05.028. [PMID: 22633931] - Csilla Hegedüs, Krisztina Truta-Feles, Géza Antalffy, György Várady, Katalin Német, Csilla Ozvegy-Laczka, György Kéri, László Orfi, Gergely Szakács, Jeffrey Settleman, András Váradi, Balázs Sarkadi. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Biochemical pharmacology.
2012 Aug; 84(3):260-7. doi:
10.1016/j.bcp.2012.04.010. [PMID: 22548830] - Mukul Minocha, Varun Khurana, Ashim K Mitra. Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Jul; 901(?):85-92. doi:
10.1016/j.jchromb.2012.06.004. [PMID: 22749591] - B Benjamin, M Sahu, U Bhatnagar, D Abhyankar, N R Srinivas. The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds?.
Arzneimittel-Forschung.
2012 Apr; 62(4):194-201. doi:
10.1055/s-0031-1299772. [PMID: 22290114] - Jeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, Deborah Schrag, Peter C Enzinger, Jennifer A Chan, Matthew H Kulke, Brian M Wolpin, Michael Goldstein, Lawrence Blaszkowsky, Andrew X Zhu, Meaghan Elliott, Eileen Regan, Rakesh K Jain, Dan G Duda. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
PloS one.
2012; 7(6):e38231. doi:
10.1371/journal.pone.0038231. [PMID: 22701615] - Paul Martin, Stuart Oliver, Sarah-Jane Kennedy, Elizabeth Partridge, Michael Hutchison, David Clarke, Petrina Giles. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Clinical therapeutics.
2012 Jan; 34(1):221-37. doi:
10.1016/j.clinthera.2011.11.011. [PMID: 22206795] - Boonchu Kulapaditharom, Vipa Boonkitticharoen, Chanika Sritara. Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma.
Journal of oncology.
2012; 2012(?):687934. doi:
10.1155/2012/687934. [PMID: 22220170] - José M Gómez Sáez. Diagnostic and prognostic markers in differentiated thyroid cancer.
Current genomics.
2011 Dec; 12(8):597-608. doi:
10.2174/138920211798120826. [PMID: 22654559] - Shun-Chieh Yang, Su-Sen Chang, Hsin-Yi Chen, Calvin Yu-Chian Chen. Identification of potent EGFR inhibitors from TCM Database@Taiwan.
PLoS computational biology.
2011 Oct; 7(10):e1002189. doi:
10.1371/journal.pcbi.1002189. [PMID: 22022246] - Luis R de Brito, Mike A Batey, Yan Zhao, Matt S Squires, Helen Maitland, Hing Y Leung, Andrew G Hall, Graham Jackson, David R Newell, Julie A E Irving. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Leukemia research.
2011 Sep; 35(9):1233-40. doi:
10.1016/j.leukres.2011.01.011. [PMID: 21316102] - Maryse Brassard, Barbara Neraud, Séverine Trabado, Sylvie Salenave, Sylvie Brailly-Tabard, Isabelle Borget, Eric Baudin, Sophie Leboulleux, Philippe Chanson, Martin Schlumberger, Jacques Young. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.
The Journal of clinical endocrinology and metabolism.
2011 Sep; 96(9):2741-9. doi:
10.1210/jc.2010-2771. [PMID: 21715537] - Feng Bai, Jennifer Johnson, Fan Wang, Lei Yang, Alberto Broniscer, Clinton F Stewart. Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2011 Sep; 879(25):2561-6. doi:
10.1016/j.jchromb.2011.07.012. [PMID: 21803003] - Sandra R Brave, Rajesh Odedra, Neil H James, Neil R Smith, Gayle B Marshall, Kerry L Acheson, Dawn Baker, Zoe Howard, Lynsay Jackson, Kirsty Ratcliffe, Anna Wainwright, Susan C Lovick, D Mark Hickinson, Robert W Wilkinson, Simon T Barry, Georgina Speake, Anderson J Ryan. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
International journal of oncology.
2011 Jul; 39(1):271-8. doi:
10.3892/ijo.2011.1022. [PMID: 21537841] - Erica L Mayer, Susan M Dallabrida, Maria A Rupnick, Whitney M Redline, Keri Hannagan, Nesreen S Ismail, Harold J Burstein, Joshua A Beckman. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.
Hypertension (Dallas, Tex. : 1979).
2011 Jul; 58(1):85-92. doi:
10.1161/hypertensionaha.110.168120. [PMID: 21482957] - Shivaani Kummar, Martin E Gutierrez, Alice Chen, Ismail B Turkbey, Deborah Allen, Yvonne R Horneffer, Lamin Juwara, Liang Cao, Yunkai Yu, Yeong Sang Kim, Jane Trepel, Helen Chen, Peter Choyke, Giovanni Melillo, Anthony J Murgo, Jerry Collins, James H Doroshow. Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
European journal of cancer (Oxford, England : 1990).
2011 May; 47(7):997-1005. doi:
10.1016/j.ejca.2010.12.016. [PMID: 21247755] - Mitra Niafar, Shahram Dabiri, Farshid Bozorgi, Farid Niafar, Nasrin Gholami. Metastatic medullary thyroid carcinoma: A case report.
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.
2011 Apr; 16(4):568-73. doi:
NULL. [PMID: 22091276] - Pankaj Bhargava, Murray O Robinson. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Current oncology reports.
2011 Apr; 13(2):103-11. doi:
10.1007/s11912-011-0154-3. [PMID: 21318618] - Rob Brierley. 2011 ASCO Genitourinary Cancers Symposium.
The Lancet. Oncology.
2011 Apr; 12(4):330. doi:
10.1016/s1470-2045(11)70089-4. [PMID: 21598448] - Tetsuki Kato, Yoshiya Ito, Kanako Hosono, Tatsunori Suzuki, Hideaki Tamaki, Tsutomu Minamino, Shintaro Kato, Hiroyuki Sakagami, Masabumi Shibuya, Masataka Majima. Vascular endothelial growth factor receptor-1 signaling promotes liver repair through restoration of liver microvasculature after acetaminophen hepatotoxicity.
Toxicological sciences : an official journal of the Society of Toxicology.
2011 Mar; 120(1):218-29. doi:
10.1093/toxsci/kfq366. [PMID: 21135413] - Li Zhang, Su Li, Yang Zhang, Jing Zhan, Ben-Yan Zou, Robert Smith, Paul D Martin, Yinrui Jiang, Hai Liao, Zhongzhen Guan. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Clinical therapeutics.
2011 Mar; 33(3):315-27. doi:
10.1016/j.clinthera.2011.04.005. [PMID: 21600385] - Paul Martin, Stuart Oliver, Jane Robertson, Sarah-Jane Kennedy, Jessica Read, Thierry Duvauchelle. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Drugs in R&D.
2011; 11(1):37-51. doi:
10.2165/11586980-000000000-00000. [PMID: 21410294] - Jeannette C Oosterwijk-Wakka, Gürsah Kats-Ugurlu, William P J Leenders, Lambertus A L M Kiemeney, Lloyd J Old, Peter F A Mulders, Egbert Oosterwijk. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
BJU international.
2011 Jan; 107(1):118-25. doi:
10.1111/j.1464-410x.2010.09314.x. [PMID: 20346054] - Alberto Broniscer, Justin N Baker, Michael Tagen, Arzu Onar-Thomas, Richard J Gilbertson, Andrew M Davidoff, Atmaram S Pai Panandiker, Atmaram Pai Panandiker, Wing Leung, Thomas K Chin, Clinton F Stewart, Mehmet Kocak, Christopher Rowland, Thomas E Merchant, Sue C Kaste, Amar Gajjar. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010 Nov; 28(31):4762-8. doi:
10.1200/jco.2010.30.3545. [PMID: 20921456] - Vijaya Karoor, Mysan Le, Daniel Merrick, Edward C Dempsey, York E Miller. Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Cancer prevention research (Philadelphia, Pa.).
2010 Sep; 3(9):1141-7. doi:
10.1158/1940-6207.capr-10-0005. [PMID: 20647338] - Angelika Weil, Paul Martin, Robert Smith, Stuart Oliver, Peter Langmuir, Jessica Read, Karl-Heinz Molz. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Clinical pharmacokinetics.
2010 Sep; 49(9):607-18. doi:
10.2165/11534330-000000000-00000. [PMID: 20690783] - K Brookes, J Cummings, A Backen, A Greystoke, T Ward, G C Jayson, C Dive. Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.
British journal of cancer.
2010 May; 102(10):1524-32. doi:
10.1038/sj.bjc.6605661. [PMID: 20407440] - Martin Goerner, Tanguy Y Seiwert, Holger Sudhoff. Molecular targeted therapies in head and neck cancer--an update of recent developments-.
Head & neck oncology.
2010 Apr; 2(?):8. doi:
10.1186/1758-3284-2-8. [PMID: 20398256] - Samuel A Wells, Jessica E Gosnell, Robert F Gagel, Jeffrey Moley, David Pfister, Julie A Sosa, Michael Skinner, Annetta Krebs, James Vasselli, Martin Schlumberger. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010 Feb; 28(5):767-72. doi:
10.1200/jco.2009.23.6604. [PMID: 20065189] - Christina M Annunziata, Amanda J Walker, Lori Minasian, Minshu Yu, Herbert Kotz, Bradford J Wood, Katherine Calvo, Peter Choyke, Daniel Kimm, Seth M Steinberg, Elise C Kohn. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010 Jan; 16(2):664-72. doi:
10.1158/1078-0432.ccr-09-2308. [PMID: 20068097] - Emer O Hanrahan, Heather Y Lin, Edward S Kim, Shaoyu Yan, Danny Z Du, Kathryn S McKee, Hai T Tran, J Jack Lee, Anderson J Ryan, Peter Langmuir, Bruce E Johnson, John V Heymach. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010 Jan; 28(2):193-201. doi:
10.1200/jco.2009.22.4279. [PMID: 19949019] - N Murukesh, C Dive, G C Jayson. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.
British journal of cancer.
2010 Jan; 102(1):8-18. doi:
10.1038/sj.bjc.6605483. [PMID: 20010945] - Sachin Kumar, Randeep Guleria, Vikas Singh, Alok C Bharti, Anant Mohan, Bhudev C Das. Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer.
BMC cancer.
2009 Dec; 9(?):421. doi:
10.1186/1471-2407-9-421. [PMID: 19958548] - Marta Cesca, Roberta Frapolli, Alexander Berndt, Valentina Scarlato, Petra Richter, Hartwig Kosmehl, Maurizio D'Incalci, Anderson J Ryan, Raffaella Giavazzi. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
Neoplasia (New York, N.Y.).
2009 Nov; 11(11):1155-64. doi:
10.1593/neo.09866. [PMID: 19881951] - Masahiro Sugawara, David L Geffner, Dorothy Martinez, Jerome M Hershman. Novel treatment of medullary thyroid cancer.
Current opinion in endocrinology, diabetes, and obesity.
2009 Oct; 16(5):367-72. doi:
10.1097/med.0b013e3283304f0c. [PMID: 19633548] - Emer O Hanrahan, Anderson J Ryan, Helen Mann, Sarah J Kennedy, Peter Langmuir, Ronald B Natale, Roy S Herbst, Bruce E Johnson, John V Heymach. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009 May; 15(10):3600-9. doi:
10.1158/1078-0432.ccr-08-2568. [PMID: 19447868] - Francesca Carlomagno, Teresa Guida, Suresh Anaganti, Livia Provitera, Svend Kjaer, Neil Q McDonald, Anderson J Ryan, Massimo Santoro. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
Endocrine-related cancer.
2009 Mar; 16(1):233-41. doi:
10.1677/erc-08-0213. [PMID: 19029224] - Sanziana Roman, Pritesh Mehta, Julie Ann Sosa. Medullary thyroid cancer: early detection and novel treatments.
Current opinion in oncology.
2009 Jan; 21(1):5-10. doi:
10.1097/cco.0b013e32831ba0b3. [PMID: 19125012] - Erica L Bradshaw-Pierce, Courtney A Steinhauer, David Raben, Daniel L Gustafson. Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.
Molecular cancer therapeutics.
2008 Sep; 7(9):3006-17. doi:
10.1158/1535-7163.mct-08-0370. [PMID: 18790781] - Katsuyuki Kiura, Kazuhiko Nakagawa, Tetsu Shinkai, Kenji Eguchi, Yuichiro Ohe, Nobuyuki Yamamoto, Masahiro Tsuboi, Soichiro Yokota, Takashi Seto, Haiyi Jiang, Kazuto Nishio, Nagahiro Saijo, Masahiro Fukuoka. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2008 Apr; 3(4):386-93. doi:
10.1097/jto.0b013e318168d228. [PMID: 18379357] - Mattias K Andersson, Pierre Aman. Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib.
Cancer cell international.
2008 Jan; 8(?):1. doi:
10.1186/1475-2867-8-1. [PMID: 18177496] - D P Bradley, J L Tessier, D Checkley, H Kuribayashi, J C Waterton, J Kendrew, S R Wedge. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
NMR in biomedicine.
2008 Jan; 21(1):42-52. doi:
10.1002/nbm.1161. [PMID: 17458919] - Teresa Troiani, Natalie J Serkova, Daniel L Gustafson, Thomas K Henthorn, Owen Lockerbie, Andrea Merz, Michael Long, Mark Morrow, Fortunato Ciardiello, S Gail Eckhardt. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007 Nov; 13(21):6450-8. doi:
10.1158/1078-0432.ccr-07-1094. [PMID: 17975157] - Andrew Advani, Darren J Kelly, Suzanne L Advani, Alison J Cox, Kerri Thai, Yuan Zhang, Kathryn E White, Renae M Gow, Sally M Marshall, Brent M Steer, Philip A Marsden, P Elizabeth Rakoczy, Richard E Gilbert. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions.
Proceedings of the National Academy of Sciences of the United States of America.
2007 Sep; 104(36):14448-53. doi:
10.1073/pnas.0703577104. [PMID: 17726104] - Viktor Johanson, Håkan Ahlman, Peter Bernhardt, Svante Jansson, Lars Kölby, Fredrik Persson, Göran Stenman, Christina Swärd, Bo Wängberg, Mats Stridsberg, Ola Nilsson. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Endocrine-related cancer.
2007 Jun; 14(2):433-44. doi:
10.1677/erc-06-0033. [PMID: 17639056] - Tomohide Tamura, Hironobu Minami, Yasuhide Yamada, Noboru Yamamoto, Tatsu Shimoyama, Haruyasu Murakami, Atsushi Horiike, Yasuhito Fujisaka, Tetsu Shinkai, Makoto Tahara, Kenji Kawada, Hiromichi Ebi, Yasutsuna Sasaki, Haiyi Jiang, Nagahiro Saijo. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2006 Nov; 1(9):1002-9. doi:
NULL. [PMID: 17409986] - Michael J Kovacs, Donna E Reece, Deborah Marcellus, Ralph M Meyer, Sarah Mathews, Rui-Ping Dong, Elizabeth Eisenhauer. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145.
Investigational new drugs.
2006 Nov; 24(6):529-35. doi:
10.1007/s10637-006-9022-7. [PMID: 16791411] - Daniel L Gustafson, Erica L Bradshaw-Pierce, Andrea L Merz, Joseph A Zirrolli. Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing.
The Journal of pharmacology and experimental therapeutics.
2006 Aug; 318(2):872-80. doi:
10.1124/jpet.106.102376. [PMID: 16644900] - M Bayes, X Rabasseda, J R Prous. Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology.
2006 Mar; 28(2):121-42. doi:
. [PMID: 16636723] - Seiji Yano, Hiroaki Muguruma, Yuka Matsumori, Hisatsugu Goto, Emiko Nakataki, Nobutaka Edakuni, Hideki Tomimoto, Soji Kakiuchi, Akihiko Yamamoto, Hisanori Uehara, Anderson Ryan, Saburo Sone. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2005 Dec; 11(24 Pt 1):8789-98. doi:
10.1158/1078-0432.ccr-05-0674. [PMID: 16361567] - Allan Wissner, M Brawner Floyd, Bernard D Johnson, Heidi Fraser, Charles Ingalls, Thomas Nittoli, Russell G Dushin, Carolyn Discafani, Ramaswamy Nilakantan, Joseph Marini, Malini Ravi, Kinwang Cheung, Xingzhi Tan, Sylvia Musto, Tami Annable, Marshall M Siegel, Frank Loganzo. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
Journal of medicinal chemistry.
2005 Dec; 48(24):7560-81. doi:
10.1021/jm050559f. [PMID: 16302797] - Joseph A Zirrolli, Erica L Bradshaw, Michael E Long, Daniel L Gustafson. Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.
Journal of pharmaceutical and biomedical analysis.
2005 Sep; 39(3-4):705-11. doi:
10.1016/j.jpba.2005.04.024. [PMID: 15935603] - Brian Nicholson, Kathryn Gulding, Mark Conaway, Stephen R Wedge, Dan Theodorescu. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2004 Dec; 10(24):8728-34. doi:
10.1158/1078-0432.ccr-04-0902. [PMID: 15623658] - Dietmar W Siemann, Wenyin Shi. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
International journal of radiation oncology, biology, physics.
2004 Nov; 60(4):1233-40. doi:
10.1016/j.ijrobp.2004.08.002. [PMID: 15519796] - J Drevs, M A Konerding, T Wolloscheck, S R Wedge, A J Ryan, D J Ogilvie, N Esser. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.
Angiogenesis.
2004; 7(4):347-54. doi:
10.1007/s10456-005-1394-3. [PMID: 15886878] - Laurent F Hennequin, Elaine S E Stokes, Andrew P Thomas, Craig Johnstone, Patrick A Plé, Donald J Ogilvie, Michael Dukes, Stephen R Wedge, Jane Kendrew, Jon O Curwen. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
Journal of medicinal chemistry.
2002 Mar; 45(6):1300-12. doi:
10.1021/jm011022e. [PMID: 11881999]